Masters Capital Management LLC bought a new stake in bluebird bio Inc (NASDAQ:BLUE) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 125,000 shares of the biotechnology company’s stock, valued at approximately $22,263,000. Masters Capital Management LLC owned approximately 0.25% of bluebird bio at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Two Sigma Advisers LP raised its stake in shares of bluebird bio by 3,004.0% during the fourth quarter. Two Sigma Advisers LP now owns 462,500 shares of the biotechnology company’s stock worth $82,371,000 after acquiring an additional 447,600 shares in the last quarter. Eagle Asset Management Inc. purchased a new stake in shares of bluebird bio during the 3rd quarter valued at about $29,539,000. BlackRock Inc. increased its position in shares of bluebird bio by 6.4% during the 4th quarter. BlackRock Inc. now owns 3,831,371 shares of the biotechnology company’s stock valued at $682,366,000 after purchasing an additional 231,697 shares during the last quarter. American Century Companies Inc. bought a new position in shares of bluebird bio during the 3rd quarter valued at approximately $31,170,000. Finally, Franklin Resources Inc. grew its stake in shares of bluebird bio by 41.3% during the 4th quarter. Franklin Resources Inc. now owns 686,900 shares of the biotechnology company’s stock valued at $122,337,000 after acquiring an additional 200,900 shares during the period.
BLUE has been the subject of a number of recent research reports. BMO Capital Markets set a $215.00 price objective on bluebird bio and gave the company a “buy” rating in a research note on Monday, December 11th. Jefferies Group upgraded bluebird bio from a “hold” rating to a “buy” rating and upped their price target for the stock from $130.00 to $211.00 in a research note on Monday, December 11th. Canaccord Genuity started coverage on bluebird bio in a research note on Tuesday, December 5th. They issued a “buy” rating and a $202.00 price target for the company. Maxim Group upped their price target on bluebird bio from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, November 30th. Finally, SunTrust Banks upped their price target on bluebird bio to $223.00 and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. bluebird bio presently has an average rating of “Hold” and an average target price of $187.60.
bluebird bio Inc (NASDAQ BLUE) opened at $231.95 on Monday. The firm has a market capitalization of $11,593.68, a P/E ratio of -30.28 and a beta of 2.06. bluebird bio Inc has a 12-month low of $74.45 and a 12-month high of $234.25.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.84). The company had revenue of $4.17 million for the quarter, compared to analysts’ expectations of $7.11 million. bluebird bio had a negative net margin of 947.42% and a negative return on equity of 28.09%. The firm’s revenue was up 169.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.88) earnings per share. analysts expect that bluebird bio Inc will post -8.25 EPS for the current fiscal year.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.